CytomX Therapeutics, Inc. - CTMX Income before deduction of interest, taxes and amortization

Brandmark of CytomX Pharma (CTMX)

CytomX Therapeutics (CTMX) develops "smart" Probody antibodies that activate strictly within tumors to protect healthy tissues. The GURU.Markets chart shows a pivot in absolute operating profit, driven by global corporate demand for targeted therapy and the protection of patents against dumping. The current status is 0.00, confirming that price action depends on the results of clinical trials with pharma behemoths.

CTMX: CytomX Corp Profit before payment of interest, taxes and amortization 11/23/2025 - 11/10/2026

CytomX Therapeutics, Inc. - analytical breakdowns and key metrics (CTMX)

- market value and analyst target forecast:
Market Price CytomX Corp|CTMX - Consensus Target
- issuer market value details:
Market Value CytomX Therapeutics|CTMX - Total Company Value
- book capitalization information:
Share Book Value CytomX Therapeutics|CTMX - Company Book Value|Market Value to Book Value Ratio cytomx.com|CTMX - Company Total Assets
- debt level and financial liquidity data:
Total Debt to Capital CytomX Therapeutics|CTMX - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio CytomX Pharma|CTMX - Company Aggregate Debts|Debts to Book Capitalization Ratio CytomX Therapeutics|CTMX - Company Long-Term Debt|Short-Term Debt CytomX Therapeutics|Intermediate Coverage Ratio cytomx.com
- earnings and valuation multiples information:
CTMX - Company Net Income|Future Profit CytomX Therapeutics|CTMX - Price to Earnings Ratio|Market Cap to Projected Earnings cytomx.com|CTMX - PEG Multiple|Enterprise Value to EBITDA Ratio CytomX Therapeutics|CTMX - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months CytomX Therapeutics|CTMX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months cytomx.com|CTMX - Earnings per share growth in current year|Expected net earnings per share growth next year CytomX Therapeutics
Summary company analytics:CytomX Corp, CTMX
Original product of cytomx.com

For the biotech sector company CytomX Therapeutics (CTMX), where capitalization depends on the versatility of drug activation platforms, this indicator serves as a measure of intellectual property monetization efficiency between quarterly reports. An analysis of EBITDA allows for the tracking of daily cash flow from core operations, where any sharp deviations in the curve signal risks of asset value drawdown.

Competitors of CytomX Therapeutics (CTMX)

Geron Bio (GERN) - Profit before interest, taxes and amortization|NBTX: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization BCYC (bicycletherapeutics.com)|perspectivetherapeutics.com (CATX) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization GNLX (Genelux)|Profit before payment of interest, taxes and amortization Molecular Partners AG|Profit before payment of interest, taxes and amortization ONCY|Operating profit EBITDA LSTA|Operating profit EBITDA moleculin.com (MBRX)|Galera Therapeutics, Inc. - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization MTEM (Molecular Templates Inc)